methsuximide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1758 77-41-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mesuximid
  • methsuximide
  • celontin
  • mesuximide
  • mesuximidum
  • methsuximid
  • racemic methsuximide
  • (+/-)-Mesuximide
anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation
  • Molecular weight: 203.24
  • Formula: C12H13NO2
  • CLOGP: 1.26
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 37.38
  • ALOGS: -1.98
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.90 g O

ADMET properties:

PropertyValueReference
S (Water solubility) 2.80 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Feb. 8, 1957 FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AD03 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
FDA EPC N0000175753 Anti-epileptic Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Absence seizure indication 79631006
Epilepsy indication 84757009 DOID:1826
Epilepsy characterized by intractable complex partial seizures off-label use 442481002
Suicidal thoughts contraindication 6471006
Depressive disorder contraindication 35489007
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Aggressive behavior contraindication 61372001
Kidney disease contraindication 90708001 DOID:557
Acute intermittent porphyria contraindication 234422006 DOID:3890
Disease of liver contraindication 235856003 DOID:409
Neutropenic disorder contraindication 303011007 DOID:1227




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
300MG METHSUXIMIDE NOVITIUM PHARMA A217213 May 1, 2023 RX CAPSULE ORAL Oct. 28, 2023 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Voltage-gated T-type calcium channel Ion channel BLOCKER CHEMBL CHEMBL

External reference:

IDSource
4018637 VUID
N0000146950 NUI
D00404 KEGG_DRUG
4018637 VANDF
C0109002 UMLSCUI
CHEBI:6846 CHEBI
CHEMBL697 ChEMBL_ID
DB05246 DRUGBANK_ID
6476 PUBCHEM_CID
C100286 MESH_SUPPLEMENTAL_RECORD_UI
7228 IUPHAR_LIGAND_ID
582 INN_ID
0G76K8X6C0 UNII
225235 RXNORM
105 MMSL
367184 MMSL
5084 MMSL
d00292 MMSL
001630 NDDF
386187007 SNOMEDCT_US
58325006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Celontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-0525 CAPSULE 300 mg ORAL NDA 19 sections
Celontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-0525 CAPSULE 300 mg ORAL NDA 19 sections
Methsuximide Human Prescription Drug Label 1 70954-228 CAPSULE 300 mg ORAL ANDA 17 sections